Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $80.00

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $79.8462.

ANAB has been the subject of several research analyst reports. Leerink Partners set a $90.00 price objective on AnaptysBio in a research report on Friday, May 15th. Barclays increased their target price on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. TD Cowen cut their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. UBS Group upped their price target on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Scotiabank downgraded shares of AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a research report on Tuesday, August 25th.

AnaptysBio Price Performance

Shares of ANAB opened at $57.03 on Friday. The company has a market capitalization of $1.69 billion, a P/E ratio of -52.81 and a beta of 0.72. AnaptysBio has a one year low of $11.40 and a one year high of $72.36. The business’s 50 day simple moving average is $58.49 and its 200-day simple moving average is $59.17.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of AnaptysBio during the second quarter valued at approximately $124,473,000. California State Teachers Retirement System raised its position in AnaptysBio by 8,399.7% in the 2nd quarter. California State Teachers Retirement System now owns 1,189,958 shares of the biotechnology company’s stock worth $80,322,000 after purchasing an additional 1,175,958 shares during the last quarter. Palo Alto Investors LP acquired a new position in AnaptysBio during the 2nd quarter worth $40,735,508. Affinity Asset Advisors LLC lifted its holdings in AnaptysBio by 111.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after buying an additional 495,308 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in AnaptysBio in the 2nd quarter valued at $28,202,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.